GlassScriptPhysician profile
Mark L Riley
NPI 1295239507
$4,600.13
in general payments reported to CMS, 2019-2025
17 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $36.48 · 2023: $1,808 · 2024: $1,162 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,511 · Travel and Lodging: $952 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,511.41 |
| Travel and Lodging | $952.25 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $1,292.25 | 2023 | |
| Abbvie INC. | $1,062.85 | 2023-2025 | Rinvoq |
| Amgen INC. | $739.80 | 2024-2025 | Krystexxa, Uplizna, Evenity |
| Novartis Pharmaceuticals Corporation | $281.68 | 2024-2025 | |
| Pfizer INC. | $259.26 | 2024-2025 | |
| Janssen Biotech, INC. | $212.96 | 2023-2025 | Tremfya |
| Horizon Therapeutics Plc | $150.00 | 2023 | Krystexxa |
| Ucb, INC. | $147.01 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $125.33 | 2023 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.05 | 2023-2025 | Ofev |
| Radius Health, INC. | $56.24 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $54.53 | 2024 | Arcalyst |
| Merz Pharmaceuticals, LLC | $36.48 | 2022 | |
| Zimmer Biomet Holdings, INC. | $29.56 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Kiniksa Pharmaceuticals, LTD. | $27.86 | 2023 | Arcalyst |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $20.13 | 2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $15.14 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.